Xeleris V Processing and Review System

The Xeleris V Processing and Review System is a software platform designed to enhance clinical diagnostics by providing comprehensive tools for processing, reviewing, and quantifying nuclear medicine images from various modalities like SPECT and PET. It employs advanced algorithms for specific clinical applications, including multi-modality image fusion, quantitative analysis for disease assessment (e.g., neurological, cardiac, oncological), and introduces new capabilities for personalized radiation dose monitoring (Q.Thera AI) and derived planar image generation (Generate Planar).

The Xeleris V Processing and Review System is a comprehensive software platform designed for nuclear medicine and radiology practitioners. It facilitates the display, processing, archiving, printing, reporting, and networking of various nuclear medicine imaging (NMI) data, including planar scans (Static, Whole Body, Dynamic, Multi-Gated) and tomographic scans (SPECT, Gated SPECT, dedicated PET, or Camera-Based-PET). The system can integrate NMI or PET data with registered and/or fused CT or MR scans, along with physiological signals, to accurately depict, localize, and quantify the distribution of radionuclide tracers and anatomical structures within the body for clinical diagnostic purposes. It supports operation on dedicated workstations or in a server-client configuration. The system includes several specialized applications such as DaTQUANT for Parkinson's disease assessment, Q.Lung AI for diagnosing lung conditions and pre-surgical lung function assessment, Q.Brain for evaluating brain metabolism/blood flow in various neurological disorders, Alcyone CFR for quantifying coronary vascular function in CAD, Exini Bone for monitoring bone metastases in prostate cancer, and Q.Liver for aiding in Selective Internal Radiation Therapy (SIRT) planning. This iteration introduces Q.Thera AI, which enhances dosimetry capabilities by estimating isotope residence time and calculating absorbed radiation doses (organ-level and whole-body effective dose) from SPECT/CT, PET/CT, planar images, and biological samples, following MIRD and ICRP guidelines. It also adds the Generate Planar application, which produces 2D derived planar images from 3D SPECT images, now supporting both SPECT-CT and SPECT-only studies.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the Q.Thera AI application's automated organ segmentation using Q.Volumetrix MI compare in accuracy and efficiency to manual segmentation or other semi-automated methods for dosimetry calculations across different anatomies and imaging modalities (SPECT/CT, PET/CT)?; What is the validated range of accuracy for the Generate Planar application in producing 2D derived planar images from SPECT-only studies, particularly concerning attenuation correction and quantitative fidelity compared to traditionally acquired planar images or SPECT-CT derived planars?; For the Q.Brain application, what specific algorithms or normalization techniques are employed to quantify relative changes in brain metabolic function or blood flow against control databases, and how is inter-subject variability handled?; Can the Q.Liver application's 'liver to lung' shunt value calculation for SIRT planning be customized or validated against phantom studies for various isotopes and SPECT/PET systems beyond default parameters?; What are the limitations of the Exini Bone application's Bone Scan Index in reflecting true disease progression in prostate cancer patients with atypical metastatic patterns or those undergoing novel therapies that might alter bone scan appearance without changing lesion burden?